Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Covington
US Army
McKesson
Boehringer Ingelheim
Citi
Julphar
Fuji
QuintilesIMS
Johnson and Johnson

Generated: October 18, 2017

DrugPatentWatch Database Preview

MINOCIN Drug Profile

« Back to Dashboard

What is the patent landscape for Minocin, and when can generic versions of Minocin launch?

Minocin is a drug marketed by Triax Pharms, Lederle, Rempex Pharms Inc, and Precision Dermat. and is included in five NDAs. There are two patents protecting this drug.

This drug has twenty-three patent family members in twenty countries.

The generic ingredient in MINOCIN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for Tradename: MINOCIN

US Patents:2
Applicants:4
NDAs:5
Suppliers / Packagers: see list4
Bulk Api Vendors: see list74
Clinical Trials: see list31
Patent Applications: see list1,589
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MINOCIN at DailyMed

Pharmacology for Tradename: MINOCIN

Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Triax Pharms
MINOCIN
minocycline hydrochloride
CAPSULE;ORAL050315-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Precision Dermat
MINOCIN
minocycline hydrochloride
CAPSULE;ORAL050649-001May 31, 1990ABRXNoNo► Subscribe► Subscribe► Subscribe
Rempex Pharms Inc
MINOCIN
minocycline hydrochloride
INJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe ► Subscribe
Precision Dermat
MINOCIN
minocycline hydrochloride
CAPSULE;ORAL050649-003Feb 12, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
Triax Pharms
MINOCIN
minocycline hydrochloride
CAPSULE;ORAL050315-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lederle
MINOCIN
minocycline hydrochloride
INJECTABLE;INJECTION062139-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Precision Dermat
MINOCIN
minocycline hydrochloride
SUSPENSION;ORAL050445-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Rempex Pharms Inc
MINOCIN
minocycline hydrochloride
INJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe ► Subscribe
Precision Dermat
MINOCIN
minocycline hydrochloride
CAPSULE;ORAL050649-002May 31, 1990ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: MINOCIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,744,179Tetracycline compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MINOCIN

Country Document Number Estimated Expiration
Denmark2568987► Subscribe
Spain2613738► Subscribe
Israel222896► Subscribe
Japan6025712► Subscribe
Russian Federation2012147527► Subscribe
Japan2016145253► Subscribe
Mexico2012012993► Subscribe
European Patent Office3135289► Subscribe
Chile2012003168► Subscribe
South Korea20130080797► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Moodys
Cerilliant
McKinsey
Farmers Insurance
UBS
Covington
Cipla
Argus Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot